SGLT-2 inhibitors in peritoneal dialysis patients

Volume overload is associated with high mortality in peritoneal dialysis patients. This overload is incompletely corrected by diuretics, fluid restriction or icodextrin-based solutions. Alternative strategies are therefore required. In this multicenter, randomized, double-blind, placebo-controlled clinical trial, investigators are evaluating the value of SGLT-2 inhibitors for reducing volume overload in patients undergoing peritoneal dialysis. At least 36 randomized patients must be recruited. The primary endpoint is the change in daily ultrafiltration volume from baseline to week 8. Key secondary endpoints include changes in biomarkers, residual renal function and anemia-related parameters.